PDGFR2 (Platelet derived growth factor receptor alpha), also known as PDGFRα, CD140A or CD140 antigen-like family member A, is an enzyme with 1089 amino acids length and a molecular mass of 122.7 kDa. In humans, it is encoded by the PDGFRA gene located on the chromosome 4q12. PDGFR2 belongs to the tyrosine protein kinase superfamily and CSF-1/PDGF receptor subfamily. It functions as a cell surface receptor for PDGFA, PDGFB, and PDGFC and plays a central role in the regulation of the embryonic development, survival, chemotaxis, and tumor progression. And depending on context, PDGFR2 can up- or downregulate the cell proliferation and migration. PDGFR2 mutations have been correlated with the idiopathic hypereosinophilic syndrome, gastrointestinal stromal tumors, and many other cancers. VEGFR2 (Vascular endothelial growth factor receptor 2), also referred to Flk-1 (Fetal liver kinase 1) or KDR (Kinase insert domain receptor, a type III receptor tyrosine kinase), is a 152 kDa type V receptor tyrosine kinase of the VEGFR family, encoded by the KDR gene. This receptor is mainly expressed in endothelial cells and several vascular tumors and has been detailed in many other carcinomas, such as colorectal, mammary, lung non-small cell tumors. VEGFR2 is essential for endothelial cell functions of angiogenesis. It is a major responder to vascular endothelial growth factor signal by a phosphorylation cascade and ultimately regulates endothelial proliferation and migration. VEGFR2 is considered as a potential cell type marker based on the availability of VEGFR2 inhibitors.